Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00101829 · ClinicalTrials.gov registry record · Phase 1

Anti-CD20 Antibody Therapy for Sjogren's Syndrome

A Phase 1 study of Sjogren's Syndrome, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 1
Development phase
12
Enrollment target
2
Study locations

NCT00101829 is a Phase 1 study of Sjogren's Syndrome that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 12 participants, below the 288-participant average among 20 other Sjogren's Syndrome trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00101829, a Phase 1 study of Sjogren's Syndrome, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine the safety of the anti-CD20 antibody rituximab in treating patients with Sjogren's syndrome (SS). Rituximab is a laboratory-made antibody currently used to treat some kinds of lymphoma. Rituximab may also help people with SS, a disease of the immune system. However, the safety of rituximab in SS patients must first be established.

Conditions Studied

Sjogren's Syndrome

Interventions

  • DRUG Rituximab

Study Locations (2)

North Carolina

  • Duke University Medical Center - Durham

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2004-04
Est. Completion 2009-08
Phase Phase 1

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00101829

The ClinicalTrials.gov registry entry for NCT00101829 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 288-participant average among 20 other Sjogren's Syndrome trials with a reported enrollment target (96% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sjogren's Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Rituximab is the first listed.

NCT00101829 reports 2 study locations spanning 2 distinct geographic areas - top geographies include North Carolina, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00101829 about?

NCT00101829 is a clinical study titled "Anti-CD20 Antibody Therapy for Sjogren's Syndrome". The purpose of this study is to determine the safety of the anti-CD20 antibody rituximab in treating patients with Sjogren's syndrome (SS). Rituximab is a laboratory-made antibody currently used to treat some kinds of lymphoma. Rituximab may also help people with SS, a disease of the immune system. ...

What is the current status of trial NCT00101829?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2004-04. Estimated completion is 2009-08.

What conditions does trial NCT00101829 study?

This clinical trial studies the following conditions: Sjogren's Syndrome.

What interventions are being tested in trial NCT00101829?

The interventions under investigation include: Rituximab (DRUG).

Who is sponsoring clinical trial NCT00101829?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00101829 being conducted?

This trial has 2 study locations across North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sjogren's Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sjogren's Syndrome

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.